NCT04201756 2022-12-23Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung AdenocarcinomaShanghai Pulmonary Hospital, Shanghai, ChinaPhase 2 Completed47 enrolled